MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX), a global leader in teledermatology, is pleased to announce the appointment of veteran healthcare industry executive Paul Karam as Sales and Marketing Director, Europe, Middle East & Africa ("EMEA"), effective immediately. Mr. Karam will be reporting to the Managing Director for the EMEA region and strengthening the MedX global footprint in general and EMEA presence in particular.

Mr. Karam holds a master's degree in Biomedical Engineering from the University of Surrey in the United Kingdom. He brings 20 plus years of experience in the health care industry, where he has held several leading roles within multinational companies covering Central and Eastern Europe, Turkey, the Middle East, Africa and Pakistan markets. He has a career history with Medtronic, Molnlycke, Stryker, and several other global companies.

“Mr. Karam's strong experience and skills will be of high added value to our overall strategy in the region, as he helps develop the EMEA region with a specific focus on Turkey, the Middle East and African sub-regions. Mr. Karam will play an integral part in accelerating MedX's revenue growth prospects by activating his already well-established medical device distributors network to the benefit of MedX's skin assessment telemedicine technology in the region,” said Mr. Naman Demaghlatrous, Managing Director for EMEA.

Initially, Mr. Karam will be supporting the rollout and expansion in Turkey, Saudi Arabia, The United Arab Emirates and South Africa. He will also be responsible for new ventures and partnerships across the MEA Region and developing and executing the company marketing strategy in the EMEA region.

"We are pleased to welcome Paul to the MedX team. We are fortunate to attract a person of his calibre, and I think it speaks to the strength of our offering and the opportunity it presents in the EMEA market," stated Michael Druhan, President of Dermatological Services & Products.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Rob von der Porten, Chairman and Acting CEO MedX Health Corp

Bill Mitoulas, Investor Relations MedX Health Corp +1.416.479.9547 bill@medxhealth.com

Medx Health (TSXV:MDX)
Gráfica de Acción Histórica
De Ene 2025 a Feb 2025 Haga Click aquí para más Gráficas Medx Health.
Medx Health (TSXV:MDX)
Gráfica de Acción Histórica
De Feb 2024 a Feb 2025 Haga Click aquí para más Gráficas Medx Health.